3.11
Schlusskurs vom Vortag:
$3.18
Offen:
$3.16
24-Stunden-Volumen:
59,214
Relative Volume:
0.43
Marktkapitalisierung:
$54.54M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-24.05M
KGV:
-1.4465
EPS:
-2.15
Netto-Cashflow:
$-17.78M
1W Leistung:
-5.18%
1M Leistung:
-9.59%
6M Leistung:
-40.19%
1J Leistung:
-26.82%
Envveno Medical Corporation Stock (NVNO) Company Profile
Firmenname
Envveno Medical Corporation
Sektor
Branche
Telefon
949-261-2900
Adresse
70 DOPPLER, IRVINE
Vergleichen Sie NVNO mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
NVNO
Envveno Medical Corporation
|
3.11 | 54.54M | 0 | -24.05M | -17.78M | -2.15 |
![]()
ABT
Abbott Laboratories
|
128.22 | 222.39B | 41.95B | 13.40B | 6.49B | 7.65 |
![]()
BSX
Boston Scientific Corp
|
105.02 | 154.78B | 15.91B | 1.79B | 1.89B | 1.21 |
![]()
SYK
Stryker Corp
|
396.07 | 150.99B | 22.60B | 2.99B | 3.49B | 7.76 |
![]()
MDT
Medtronic Plc
|
90.82 | 116.46B | 33.00B | 4.29B | 5.50B | 3.27 |
![]()
EW
Edwards Lifesciences Corp
|
70.99 | 41.87B | 6.60B | 4.16B | 490.10M | 6.93 |
Envveno Medical Corporation Aktie (NVNO) Neueste Nachrichten
enVVeno Medical to Present at the Virtual Investor 2022 Top Picks Conference - ACCESS Newswire
enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity - ACCESS Newswire
enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve(R) - ACCESS Newswire
Westside Investment Management Inc. Acquires 116,650 Shares of enVVeno Medical Corporation (NASDAQ:NVNO) - MarketBeat
Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth - Yahoo Finance
enVVeno Medical Corporation (NASDAQ:NVNO) Shares Bought by Geode Capital Management LLC - Defense World
Hancock Jaffe Laboratories, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019 - Marketscreener.com
enVVeno Medical (NASDAQ:NVNO) and Sharps Technology (NASDAQ:STSS) Head to Head Survey - Defense World
Insider Buying: Francis Duhay Acquires Shares of enVVeno Medical Corp - GuruFocus.com
Envveno medical director Robert Gray buys $10,290 in shares - Investing.com India
Envveno medical director Duhay Francis buys $249,999 in stock By Investing.com - Investing.com Canada
Envveno medical director Robert Gray buys $10,290 in shares By Investing.com - Investing.com Australia
Envveno medical director Duhay Francis buys $249,999 in stock - Investing.com India
Insider Buying: Robert Gray Acquires 3,500 Shares of enVVeno Med - GuruFocus.com
enVVeno Medical Corporation (NASDAQ:NVNO) Director Purchases $10,290.00 in Stock - MarketBeat
Insider Buying: Sanjay Shrivastava Acquires Shares in enVVeno Me - GuruFocus.com
enVVeno Medical Corporation (NASDAQ:NVNO) Director Acquires $15,660.00 in Stock - MarketBeat
Envveno Medical's director Sanjay Shrivastava buys $15,660 in stock - Investing.com
Insider Buying: Matthew Jenusaitis Acquires 9,620 Shares of enVV - GuruFocus.com
Envveno medical director Matthew Jenusaitis buys $24,338 in stock By Investing.com - Investing.com Nigeria
Envveno medical director Matthew Jenusaitis buys $24,338 in stock - Investing.com India
Critical Survey: enVVeno Medical (NASDAQ:NVNO) versus Profound Medical (NASDAQ:PROF) - Defense World
NVNO stock touches 52-week low at $2.5 amid market challenges By Investing.com - Investing.com South Africa
NVNO stock touches 52-week low at $2.5 amid market challenges - Investing.com
Envveno Medical CEO Robert Berman acquires $30,599 in stock By Investing.com - Investing.com Australia
CEO Robert Berman Increases Stake in enVVeno Medical Corp with R - GuruFocus.com
Envveno Medical CEO Robert Berman acquires $30,599 in stock - Investing.com
enVVeno Medical completes final wave of implants in pre-clinical GLP study - TipRanks
enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe - AccessWire
enVVeno Medical Completes Key Pre-Clinical Study for Revolutionary Venous Valve, Advances FDA Approval Path - StockTitan
NVNO Stock Touches 52-Week Low at $2.9 Amid Market Challenges - Investing.com
NVNO Stock Touches 52-Week Low at $3.01 Amid Market Challenges - Investing.com
enVVeno launches recap website highlighting VEITH Symposium participation - TipRanks
enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website - Kansas City Star
enVVeno Medical Showcases Breakthrough VenoValve Trial Data at VEITH Symposium | NVNO Stock News - StockTitan
NVNO Completes Application for VenoValve's PMA, Shares Likely to Gain - MSN
enVVeno Medical (NASDAQ:NVNO) Is In A Good Position To Deliver On Growth Plans - Simply Wall St
Reviewing enVVeno Medical (NASDAQ:NVNO) and Cerus (NASDAQ:CERS) - Defense World
PMA application submitted for VenoValve device - Venous News
enVVeno Medical (STU:5HJ) Profitability Rank : 1 (As of Sep. 2024) - GuruFocus.com
enVVeno Medical rises on submission of the venovalve PMA application for FDA approval - MSN
One-year data from the VenoValve US pivotal trial emerge - Venous News
enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium - AccessWire
Finanzdaten der Envveno Medical Corporation-Aktie (NVNO)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):